Drugs / rhMBL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00520325 | Jun 2007 → Jun 2009 | cancer, neutropenia | Enzon Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00415311 | Dec 2006 → Jun 2009 | — | Enzon Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhMBL | “A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia” NCT00520325 ↗ |
| Known as | Recombinant Human Mannose-Binding Lectin | “Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)” NCT00415311 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Mannose-Binding Lectin” NCT00415311 ↗ |
| Route | Intravenous | “Intravenous(i.v.) administration” NCT00415311 ↗ |